

Page No. : 1 of 2
 Document No. : BM/PV/ANX/008B
 SOP Ref. No. : BM/PV/008
 Revision No. : 05
 Effective date : 17/08/2022
 To be reviewed : 16/08/2024
 Replace Revision : 04

BM CONTROLLED COPY
THIS STAMP IS RED

POST MARKETING SURVEILLANCE RECORD

Name of Executive: Mr. _____ State _____ Date of Submission _____ Period covered _____ to _____

Date, Doctor Name, Vaccine and Area visited	Conclusion		Sign
	Feedback taken on following Vaccine (Tick)	Overall Safety Evaluation	
(Typhoid Polysaccharide Vaccine) Bio Typh™	Yes/No/NA		
(Typhoid Vi Conjugate vaccine) PedaTyph™	Yes/No/NA		
(Meningococcal polysaccharide Vaccine (Group A & C) Bi Meningo™	Yes/No/NA		
(Meningococcal Polysaccharide Vaccine (Group A, C, Y & W 135) QuadriMeningo™	Yes/No/NA		
(Botulinum Toxin Type A for injection, Purified neurotoxin	Yes/No/NA		

Page No. : 2 of 2
 Document No. : BM/PV/ANX/008B
 SOP Ref. No. : BM/PV/008
 Revision No. : 05
 Effective date : 17/08/2022
 To be reviewed : 16/08/2024
 Replace Revision : 04

	complex)Botogenie™	
	Rabies Vaccine Human SURE RAB™	Yes/No/NA

Tick (✓) Yes – Mark (✓) on yes if any event /side effect reported from vaccine & go through the AEFI Reporting form BM/PV/ANX/001B

No - Mark (✓) on No if no any event /side effect reported from vaccine .

NA - Mark (✓) on NA if the concerned vaccine is not sold in that area.

Remarks: _____

Medical representative (Sign/Date):

Reviewed by Pharmacovigilance Personnel (Sign/Date):